Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

NCT05535413 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT05535413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2023
Completion date
July 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, capecitabine, metastatic her2 negative breast carcinoma, udt1